Alterity Therapeutics Welcomes Abby Macnish Niven
Alterity Therapeutics, a notable player in the biotechnology field, has appointed Abby Macnish Niven as the new Company Secretary. Her appointment follows her recent selection as the Chief Financial Officer (CFO) of the company. This transition emphasizes the leadership changes within Alterity aimed at enhancing their operational effectiveness.
Abby Macnish Niven's Professional Background
Abby comes with a wealth of experience in private wealth management, having worked with distinguished firms such as ANZ, UBS, and Ord Minett. She has a proven track record consulting for various listed and unlisted companies, specifically focusing on governance, finance, and corporate structure. Her formal education includes a Bachelor of Commerce and Bachelor of Science from the University of Western Australia, alongside being a qualified Chartered Finance Analyst.
Role Transition Details
Ms. Macnish Niven is set to take over the responsibilities of Company Secretary from her predecessor, Mr. Phillip Hains. The management team at Alterity extends gratitude to Phillip for his significant contributions during his tenure. This change not only reflects a shift in roles but also aims to streamline communications between Alterity and the ASX as well.
About Alterity Therapeutics
Alterity Therapeutics is committed to pioneering new solutions for individuals facing neurodegenerative diseases. The company is in the clinical stage and is primarily focused on developing its leading asset, ATH434, which is being evaluated in two Phase 2 clinical trials for Managing Multiple System Atrophy. Alongside their clinical pursuits, Alterity invests in a robust drug discovery platform that generates innovative compounds targeting neurological disorders.
Company Vision and Strategy
With a dual focus on clinical trials and discovery initiatives, Alterity Therapeutics remains dedicated to exploring uncharted areas in neurological research. The company's strategic vision includes continuously evaluating the potential of ATH434 and developing future therapeutic options that could significantly impact the quality of life for patients.
Investor and Media Contact Information
For inquiries, Alterity Therapeutics has designated contacts:
In Australia:
Ana Luiza Harrop
Contact: +61 452 510 255
Email: we-aualteritytherapeutics@we-worldwide.com
In the U.S.:
Remy Bernarda
Contact: +1 (415) 203-6386
Email: remy.bernarda@iradvisory.com
Frequently Asked Questions
Who is Abby Macnish Niven?
Abby Macnish Niven is the newly appointed Company Secretary at Alterity Therapeutics, also serving as the Chief Financial Officer.
What experience does Abby have?
She brings extensive experience in finance and governance from her roles at prestigious firms like ANZ and UBS.
What is Alterity Therapeutics known for?
Alterity Therapeutics is focused on developing treatments for neurodegenerative diseases, particularly through its drug ATH434.
What role did Phillip Hains play?
Phillip Hains previously served as Company Secretary and has made valuable contributions to Alterity during his tenure.
How can I contact Alterity Therapeutics?
Investor and media inquiries can be directed to Ana Luiza Harrop or Remy Bernarda through the provided contact details.
